EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

Variablen der homologen Rekombinationsreparatur-(HRR)-Gentestung und diagnostische Wege bei Prostatakrebs: multizentrische Kohortenstudie

Lorena Incorvaia iD, Mattia Puglisi, Marco Maruzzo, Giulia Mammone, Orazio Caffo, Giuseppe Procopio, Lorenzo Antonuzzo, Mimma Rizzo, Vincenza Conteduca iD, Carlo Messina, Sarah Scagliarini, Brigida Maiorano und 21 weitere

The Oncologist · 01.12.2025 · 30 (12)

DOI: 10.1093/oncolo/oyaf395 ↗

Auf einen Blick

Bei 1.400 Prostatakrebs-Patienten wurden HRR-Varianten in 17,7 % gefunden. Das Testergebnis war bei 89,7 % schlüssig und hing von Gewebeart und Testzeitpunkt ab.

Fragestellung

Welche DNA-Quelle, welches Tumorgewebe und welcher Testzeitpunkt beeinflussen den diagnostischen Weg und die Rate schlüssiger HRR-Testergebnisse bei Prostatakrebs?

Methode

Beobachtende Kohortenstudie in 20 italienischen Krebszentren; sequenzieller Einschluss von Patienten mit germinaler, Tumor- und/oder Plasma-ctDNA-HRR-Testung zwischen 1. Januar 2020 und 31. Januar 2025.

Ergebnisse

Unter 1.400 Patienten hatten 248 (17,7 %) (likely)pathogene HRR-Varianten. 779 (62,8 %) Tests erfolgten bei mCRPC. Schlüssige Resultate: 89,7 %. HRR-Alterationen: 18,1 % bei mCRPC und 13,8 % bei hormonsensitivem PC (P = .06). Tumor/ctDNA-Konkordanz: 83,9 %.

Schlussfolgerung der Autor:innen

Die Autoren sehen in der realen klinischen Testpraxis neue Einblicke in Variablen, die den Erfolg der HRR-Genomtestung beeinflussen.

Kernaussagen

  • HRR-Varianten bei 17,7 % der 1.400 Patienten
  • Schlüssige Testergebnisse in 89,7 %
  • Tumor-/ctDNA-Konkordanz: 83,9 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 02.12.2025. Verfasst von Lorena Incorvaia und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, 9…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing, Recombinational DNA Repair. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence on homologous recombination repair (HRR) mutation prevalence in prostate cancer (PC) patients and the diagnostic testing path to guide treatment remains limited outside of clinical trials. The objective of this study was to investigate the DNA source, type of tumor tissue, timing for testing in the patient’s disease course, and rate of conclusive results in a real-world population. Patients and Methods This was an observational, cohort study, involving 20 Italian cancer centers. The study population included consecutive PC patients undergoing germline, tumor, and/or plasma circulating tumor DNA (ctDNA) to profile HRR genes between January 1, 2020 and January 31, 2025.

Results

Among 1400 PC patients included, 248 (17.7%) showed (likely)pathogenic variants (PVs) in the HRR genes. Most HRR testing was conducted during the metastatic castration-resistant PC (mCRPC)(779, 62.8%). The rate of conclusive results was 89.7% and varied widely according to the type of tumor tissue. The prevalence of HRR alterations was 18.1% in the mCRPC and 13.8% in the hormone-sensitive PC (P = .06). The concordance between tumor testing and ctDNA was 83.9%. Interestingly, 4.6% reported ctDNA testing positive but tumor testing negative, leading to important therapeutic implications. The prevalence of positive ctDNA testing was 47.4% vs 10.5%, for testing within 1 month or over 3 months, respectively, from the initiation of a new line of therapy.

Conclusion

This large real-world study, through the workflow adopted by clinicians for HRR genomic testing, provides novel insights into the variables influencing the success rate of genomic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGenetic TestingRecombinational DNA RepairHumansMaleAgedMiddle AgedCohort StudiesBiomarkers, TumorCirculating Tumor DNAAged, 80 and overMutation

Stichwörter der Autor:innen

BRCAhomologous recombination deficiencyhomologous recombination repairprostate cancer

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, 90127, Italy.
  • Oncology 3 Unit, Istituto Oncologico Veneto-IOV IRCCS, Padova, 35128, Italy.
  • Medical and Translation Oncology, Azienda Ospedaliera S. Maria, Terni, 05100, Italy.
  • Department of Medical Oncology, Santa Chiara Hospital, Trento, 38122, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, 20133, Italy.
  • Clinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.

ORCID-Profile: Lorena Incorvaia, Vincenza Conteduca, Massimo Di Maio

Zitieren

APA

Incorvaia, L., Puglisi, M., Maruzzo, M., Mammone, G., Caffo, O., Procopio, G., Antonuzzo, L., Rizzo, M., Conteduca, V., Messina, C., Scagliarini, S., Maiorano, B., Santoni, M., Facchini, G., Lipari, H., Formisano, L., Stellato, M., Basso, U., Rossetti, S., …, & Russo, A. (2025). Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study. The Oncologist, 30(12). https://doi.org/10.1093/oncolo/oyaf395

Vancouver

Incorvaia L, Puglisi M, Maruzzo M, Mammone G, Caffo O, Procopio G, et al. Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study. The Oncologist. 2025;30(12). doi:10.1093/oncolo/oyaf395

BibTeX
@article{Incorvaia2025,
  author = {Incorvaia, Lorena and Puglisi, Mattia and Maruzzo, Marco and Mammone, Giulia and Caffo, Orazio and Procopio, Giuseppe and Antonuzzo, Lorenzo and Rizzo, Mimma and Conteduca, Vincenza and Messina, Carlo and Scagliarini, Sarah and Maiorano, Brigida and Santoni, Matteo and Facchini, Gaetano and Lipari, Helga and Formisano, Luigi and Stellato, Marco and Basso, Umberto and Rossetti, Sabrina and Lai, Eleonora and Arcara, Carlo Carmelo and Bronte, Enrico and Bazan Russo, Tancredi Didier and Colletta, Giovanni and Gristina, Valerio and Pepe, Francesco and Malapelle, Umberto and Santini, Daniele and Depetris, Ilaria and Di Maio, Massimo and Badalamenti, Giuseppe and Bracarda, Sergio and Russo, Antonio},
  title = {Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {12},
  doi = {10.1093/oncolo/oyaf395}
}
Kostenlos starten →